MedPath

A Study on Vallarai Chooranam in the management of Azhal Neerchurukku(Urinary Tract Infection)

Phase 2
Not yet recruiting
Conditions
Urinary tract infection, site notspecified,
Registration Number
CTRI/2025/05/086184
Lead Sponsor
Government Siddha Medical College, Chennai
Brief Summary

Urinary tract infection is the presence of microbial pathogens in the urinary tract. The incidence is high common among women.  The common feature of UTI are frequency of micturition and urgency,oliguria,dysuria.In siddha system of medicine there are unique combination of medicine one such combination of medicine is Vallarai chooranam which will be more effective and reliable .

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Patients having complaints such as Dysuria, Frequency of micturition, Burning micturition, Hematuria , Lower abdominal pain, Low backache / supra pubic pain, patients with urine culture significant for bacteria or fungus,Patients having moderate to severe symptoms according to UTI symptom assessment scale.

Exclusion Criteria

Pregnancy H/O Sexually transmitted disease H/O Malignancy H/O Diabetes mellitus.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is mainly assessed by reduction in Clinical Signs and Symptoms by UTI Symptom assessment score and also assessed by Urine Culture when bacterial/fungal infection becomes negative after treatment40 days
Secondary Outcome Measures
NameTimeMethod
By Comparing the Clinical Signs and Symptoms and the Urine Culture before and after treatment40 days

Trial Locations

Locations (1)

Government Siddha Medical College Hospital,Chennai

🇮🇳

Chennai, TAMIL NADU, India

Government Siddha Medical College Hospital,Chennai
🇮🇳Chennai, TAMIL NADU, India
Dr Priyanka S
Principal investigator
9500179263
priya22sathya@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.